MEDICINOVA, INC. Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross
MEDICINOVA, INC. (MNOV) reported Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross of $700.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross · last filed 2025-02-19
- MEDICINOVA, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2023-12-31 was $0.00.
- MEDICINOVA, INC. research and development arrangement, contract to perform for others, costs incurred, gross for the quarter ending 2023-09-30 was $700.00K.
- MEDICINOVA, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2024 was $700.00K, a 0.00% change from fiscal 2023.
- MEDICINOVA, INC. research and development arrangement, contract to perform for others, costs incurred, gross for fiscal 2023 was $700.00K.
| Period end | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 3 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 6 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 9 month | Research and Development Arrangement, Contract to Perform for Others, Costs Incurred, Gross 12 month |
|---|---|---|---|---|
| 2024-12-31 | $700.00K 10-K · filed 2025-02-19 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $700.00K derived: sum of 2 quarters · filed 2024-02-15 | $700.00K 10-K · filed 2024-02-15 | |
| 2023-09-30 | $700.00K 10-Q · filed 2023-11-09 | $700.00K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |